Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retina > Ultra-widefield and 7-field imaging proven comparable for tracking diabetic retinopathy severity
  • Retina

Ultra-widefield and 7-field imaging proven comparable for tracking diabetic retinopathy severity

Kelsey Moroz

The 7-field (7F) and ultra-widefield (UWF) imaging modalities provide highly comparable assessments of diabetic retinopathy (DR) severity, according to a study.

High concordance between these methods could allow their combined use in both clinical research and patient care over time.

The research analyzed data from the Diabetes Control and Complications Trial (DCCT) and its follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Participants with type 1 diabetes underwent both 7F and UWF imaging between 2019 and 2021, with DR severity graded using standardized scales.

Results showed strong correlations between the 2 imaging methods across various DR severity levels, including severe nonproliferative DR and proliferative DR. The study concluded that both 7F and UWF imaging provide comparable DR assessments, indicating that UWF imaging can be confidently used in future longitudinal studies without introducing significant measurement biases.

Reference
Aiello LP, Blodi B, Gao X, et al; DCCT/EDIC Research Group. Ultra-Widefield and Early Treatment Diabetic Retinopathy Study 7-Field Grading of Diabetic Retinopathy. JAMA Ophthalmol. 2024 Aug 15:e242890. doi: 10.1001/jamaophthalmol.2024.2890. Epub ahead of print. PMID: 39145984; PMCID: PMC11327899.

 

Share

Related Content

  • Retina

Aflibercept 8 mg shows comparable IOP safety to 2 mg through 96 weeks

  • Retina

Heidelberg receives FDA clearance for updated SPECTRALIS software

  • Retina

Aflibercept 8 mg demonstrates favorable safety profile in large nAMD cohort

  • Retina

Aflibercept 8 mg shows modest benefits in difficult-to-treat nAMD cases

  • Retina

AXPAXLI meets superiority endpoint in SOL-1 Phase 3 wet AMD trial

  • Diabetic Macular Edema

Hawaiian Eye Meeting update: TKI therapy may reduce treatment burden in DME and wet AMD

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon